Invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome--a case report.
We report a case of invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome, and briefly discuss the association of bladder cancer and cyclophosphamide. A 6-year-old boy, who was diagnosed as having nephrotic syndrome, was treated with oral administration of prednisolone and cyclophosphamide for 4 years, receiving a total dose of 49.5 g cyclophosphamide. At age 27, a gross hematuria with bloody clots appeared and he presented with postrenal renal failure. He underwent a radical cystourethrectomy and ileal conduit for stage a pT3a pN0 M0 transitional cell carcinoma of the bladder. He was not given any adjuvant treatments because of his renal insufficiency, and he died from the disease 14 months after radical surgery.
Nakamoto
T
T
Department of Urology, Hiroshima University School of Medicine, Japan. tnaka@mcai.med.hiroshima-u.ac.jp
Kasaoka
Y
Y
Ikegami
Y
Y
Usui
T
T
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced* / Q000175:diagnosis; D003520:Cyclophosphamide / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000175:diagnosis
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide